ZA200208177B - Cyclohexylamine derivative as subtype selective NMDA receptor antagonists. - Google Patents
Cyclohexylamine derivative as subtype selective NMDA receptor antagonists. Download PDFInfo
- Publication number
- ZA200208177B ZA200208177B ZA200208177A ZA200208177A ZA200208177B ZA 200208177 B ZA200208177 B ZA 200208177B ZA 200208177 A ZA200208177 A ZA 200208177A ZA 200208177 A ZA200208177 A ZA 200208177A ZA 200208177 B ZA200208177 B ZA 200208177B
- Authority
- ZA
- South Africa
- Prior art keywords
- cyclohexyl
- phenol
- alkyl
- aralkyl
- group
- Prior art date
Links
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title description 3
- 150000003946 cyclohexylamines Chemical class 0.000 title description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 53
- 239000001257 hydrogen Substances 0.000 claims description 53
- 125000000217 alkyl group Chemical group 0.000 claims description 47
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 36
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 23
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims description 22
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 13
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 11
- 125000001188 haloalkyl group Chemical group 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 150000001408 amides Chemical class 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 6
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 125000004001 thioalkyl group Chemical group 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 206010008118 cerebral infarction Diseases 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 201000006474 Brain Ischemia Diseases 0.000 claims description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- -1 guanidinyl Chemical group 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 206010010904 Convulsion Diseases 0.000 claims description 3
- 208000013016 Hypoglycemia Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- LHPSNJNPZAFCLK-UHFFFAOYSA-N 4-[4-(2-phenylsulfanylethylamino)cyclohexyl]phenol Chemical compound C1=CC(O)=CC=C1C1CCC(NCCSC=2C=CC=CC=2)CC1 LHPSNJNPZAFCLK-UHFFFAOYSA-N 0.000 claims description 2
- FFZAFMWWOKKINB-UHFFFAOYSA-N 4-[4-(3-phenylprop-2-ynylamino)cyclohexyl]phenol Chemical compound C1=CC(O)=CC=C1C1CCC(NCC#CC=2C=CC=CC=2)CC1 FFZAFMWWOKKINB-UHFFFAOYSA-N 0.000 claims description 2
- AGKKZDATHXMERD-UHFFFAOYSA-N 4-[4-(4-phenylbutylamino)cyclohexyl]phenol Chemical compound C1=CC(O)=CC=C1C1CCC(NCCCCC=2C=CC=CC=2)CC1 AGKKZDATHXMERD-UHFFFAOYSA-N 0.000 claims description 2
- LTVNOHYVROBAIJ-UHFFFAOYSA-N 4-[4-(5-phenylpentylamino)cyclohexyl]phenol Chemical compound C1=CC(O)=CC=C1C1CCC(NCCCCCC=2C=CC=CC=2)CC1 LTVNOHYVROBAIJ-UHFFFAOYSA-N 0.000 claims description 2
- RQCPNEISYJHKDD-UHFFFAOYSA-N 4-[4-[3-phenylpropyl(propan-2-yl)amino]cyclohexyl]phenol Chemical compound C1CC(C=2C=CC(O)=CC=2)CCC1N(C(C)C)CCCC1=CC=CC=C1 RQCPNEISYJHKDD-UHFFFAOYSA-N 0.000 claims description 2
- QPXQQOWQDOGSAY-UHFFFAOYSA-N 4-[4-[methyl(3-phenylpropyl)amino]cyclohexyl]phenol Chemical compound C1CC(C=2C=CC(O)=CC=2)CCC1N(C)CCCC1=CC=CC=C1 QPXQQOWQDOGSAY-UHFFFAOYSA-N 0.000 claims description 2
- GNSBLLWRROKPTQ-SAABIXHNSA-N C1=CC(O)=CC=C1[C@@H]1CC[C@@H](NCC=2C=CC=CC=2)CC1 Chemical compound C1=CC(O)=CC=C1[C@@H]1CC[C@@H](NCC=2C=CC=CC=2)CC1 GNSBLLWRROKPTQ-SAABIXHNSA-N 0.000 claims description 2
- TYNFYZYERIECNA-DGGRRMMCSA-N CC(CCc1ccccc1)N[C@H]1CC[C@@H](CC1)c1ccc(O)cc1 Chemical compound CC(CCc1ccccc1)N[C@H]1CC[C@@H](CC1)c1ccc(O)cc1 TYNFYZYERIECNA-DGGRRMMCSA-N 0.000 claims description 2
- SBUVMSHZGLJHMN-UAPYVXQJSA-N COc1ccc(CCN[C@H]2CC[C@@H](CC2)c2ccc(O)cc2)cc1 Chemical compound COc1ccc(CCN[C@H]2CC[C@@H](CC2)c2ccc(O)cc2)cc1 SBUVMSHZGLJHMN-UAPYVXQJSA-N 0.000 claims description 2
- TYNFYZYERIECNA-YFVAEKQCSA-N C[C@H](CCc1ccccc1)N[C@H]1CC[C@@H](CC1)c1ccc(O)cc1 Chemical compound C[C@H](CCc1ccccc1)N[C@H]1CC[C@@H](CC1)c1ccc(O)cc1 TYNFYZYERIECNA-YFVAEKQCSA-N 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 claims description 2
- 206010011878 Deafness Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- DFOACJFYXHVQDZ-MISYRCLQSA-N OC[C@@H](Cc1ccccc1)N[C@H]1CC[C@@H](CC1)c1ccc(O)cc1 Chemical compound OC[C@@H](Cc1ccccc1)N[C@H]1CC[C@@H](CC1)c1ccc(O)cc1 DFOACJFYXHVQDZ-MISYRCLQSA-N 0.000 claims description 2
- QUFRMUUIEDVKFC-RUCARUNLSA-N Oc1ccc(cc1)[C@H]1CC[C@@H](CC1)NCCc1ccc(F)cc1 Chemical compound Oc1ccc(cc1)[C@H]1CC[C@@H](CC1)NCCc1ccc(F)cc1 QUFRMUUIEDVKFC-RUCARUNLSA-N 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 230000036461 convulsion Effects 0.000 claims description 2
- 208000001763 cytomegalovirus retinitis Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 2
- 230000010370 hearing loss Effects 0.000 claims description 2
- 231100000888 hearing loss Toxicity 0.000 claims description 2
- 208000016354 hearing loss disease Diseases 0.000 claims description 2
- XBLZMYHGSZDHDT-UHFFFAOYSA-N methyl n-benzyl-n-[4-(4-hydroxyphenyl)cyclohexyl]carbamate Chemical compound C1CC(C=2C=CC(O)=CC=2)CCC1N(C(=O)OC)CC1=CC=CC=C1 XBLZMYHGSZDHDT-UHFFFAOYSA-N 0.000 claims description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- DVURNBSMLYCSNH-UHFFFAOYSA-N n-[4-(4-hydroxyphenyl)cyclohexyl]-n-(3-phenylpropyl)acetamide Chemical compound C1CC(C=2C=CC(O)=CC=2)CCC1N(C(=O)C)CCCC1=CC=CC=C1 DVURNBSMLYCSNH-UHFFFAOYSA-N 0.000 claims description 2
- LUFDITWHPQCYEI-UHFFFAOYSA-N n-benzyl-n-[4-(4-hydroxyphenyl)cyclohexyl]acetamide Chemical compound C1CC(C=2C=CC(O)=CC=2)CCC1N(C(=O)C)CC1=CC=CC=C1 LUFDITWHPQCYEI-UHFFFAOYSA-N 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 7
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims 2
- AFKFAJNGQSSQIZ-UHFFFAOYSA-N 2-(aminomethyl)-4-[4-[ethyl(3-phenylpropyl)amino]cyclohexyl]phenol Chemical compound C1CC(C=2C=C(CN)C(O)=CC=2)CCC1N(CC)CCCC1=CC=CC=C1 AFKFAJNGQSSQIZ-UHFFFAOYSA-N 0.000 claims 1
- MVRPPTGLVPEMPI-UHFFFAOYSA-N 2-cyclohexylphenol Chemical compound OC1=CC=CC=C1C1CCCCC1 MVRPPTGLVPEMPI-UHFFFAOYSA-N 0.000 claims 1
- ZSCFHZMQBFWBIC-UHFFFAOYSA-N 4-[4-(2-anilinoethylamino)cyclohexyl]phenol Chemical compound C1=CC(O)=CC=C1C1CCC(NCCNC=2C=CC=CC=2)CC1 ZSCFHZMQBFWBIC-UHFFFAOYSA-N 0.000 claims 1
- VLQMXBLFVHRNAT-UHFFFAOYSA-N 4-[4-(2-phenylethylamino)cyclohexyl]phenol Chemical compound C1=CC(O)=CC=C1C1CCC(NCCC=2C=CC=CC=2)CC1 VLQMXBLFVHRNAT-UHFFFAOYSA-N 0.000 claims 1
- MFZGWTAJGYWBEU-UHFFFAOYSA-N 4-[4-(3-phenylpropylamino)cyclohexyl]phenol Chemical compound C1=CC(O)=CC=C1C1CCC(NCCCC=2C=CC=CC=2)CC1 MFZGWTAJGYWBEU-UHFFFAOYSA-N 0.000 claims 1
- MMPGKIULWGETNC-UHFFFAOYSA-N 4-[4-[ethyl(3-phenylpropyl)amino]cyclohexyl]phenol Chemical compound C1CC(C=2C=CC(O)=CC=2)CCC1N(CC)CCCC1=CC=CC=C1 MMPGKIULWGETNC-UHFFFAOYSA-N 0.000 claims 1
- GPWBMSVTMPQJQL-UHFFFAOYSA-N 4-[4-[methyl(2-phenoxyethyl)amino]cyclohexyl]phenol Chemical compound C1CC(C=2C=CC(O)=CC=2)CCC1N(C)CCOC1=CC=CC=C1 GPWBMSVTMPQJQL-UHFFFAOYSA-N 0.000 claims 1
- BNCGEQKGSZIDSO-UAPYVXQJSA-N C1=CC(O)=CC=C1[C@@H]1CC[C@@H](NCCCC=2C=CN=CC=2)CC1 Chemical compound C1=CC(O)=CC=C1[C@@H]1CC[C@@H](NCCCC=2C=CN=CC=2)CC1 BNCGEQKGSZIDSO-UAPYVXQJSA-N 0.000 claims 1
- AGKKZDATHXMERD-XUTJKUGGSA-N Oc1ccc(cc1)[C@H]1CC[C@@H](CC1)NCCCCc1ccccc1 Chemical compound Oc1ccc(cc1)[C@H]1CC[C@@H](CC1)NCCCCc1ccccc1 AGKKZDATHXMERD-XUTJKUGGSA-N 0.000 claims 1
- YLGFODLJXHIPCG-RUCARUNLSA-N Oc1ccc(cc1)[C@H]1CC[C@@H](CC1)NCCCc1ccccn1 Chemical compound Oc1ccc(cc1)[C@H]1CC[C@@H](CC1)NCCCc1ccccn1 YLGFODLJXHIPCG-RUCARUNLSA-N 0.000 claims 1
- HOUYDKWVSLWILI-JCNLHEQBSA-N Oc1ccc(cc1)[C@H]1CC[C@@H](CC1)NCc1cccnc1 Chemical compound Oc1ccc(cc1)[C@H]1CC[C@@H](CC1)NCc1cccnc1 HOUYDKWVSLWILI-JCNLHEQBSA-N 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- RLDCTYNUILGEQM-UHFFFAOYSA-N n-[4-(4-hydroxyphenyl)cyclohexyl]-3-phenylpropanamide Chemical compound C1=CC(O)=CC=C1C1CCC(NC(=O)CCC=2C=CC=CC=2)CC1 RLDCTYNUILGEQM-UHFFFAOYSA-N 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 125000006308 propyl amino group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 6
- 229960002989 glutamic acid Drugs 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 102100022645 Glutamate receptor ionotropic, NMDA 1 Human genes 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 108010054235 NMDA receptor A1 Proteins 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 210000003568 synaptosome Anatomy 0.000 description 2
- RGZGRPPQZUQUCR-UHFFFAOYSA-N 1-phenylcyclohexylamine Chemical class C=1C=CC=CC=1C1(N)CCCCC1 RGZGRPPQZUQUCR-UHFFFAOYSA-N 0.000 description 1
- CEFQMIDTRSQENZ-VQSBYGRUSA-N 4-[4-[[(2s)-1-phenylpropan-2-yl]amino]cyclohexyl]phenol Chemical compound C([C@H](C)NC1CCC(CC1)C=1C=CC(O)=CC=1)C1=CC=CC=C1 CEFQMIDTRSQENZ-VQSBYGRUSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- TYNFYZYERIECNA-CUWPLCDZSA-N C[C@@H](CCc1ccccc1)N[C@H]1CC[C@@H](CC1)c1ccc(O)cc1 Chemical compound C[C@@H](CCc1ccccc1)N[C@H]1CC[C@@H](CC1)c1ccc(O)cc1 TYNFYZYERIECNA-CUWPLCDZSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 229940123511 Excitatory amino acid receptor antagonist Drugs 0.000 description 1
- 102100022626 Glutamate receptor ionotropic, NMDA 2D Human genes 0.000 description 1
- 101710195184 Glutamate receptor ionotropic, NMDA 2D Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 208000001393 Lathyrism Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 208000006079 Near drowning Diseases 0.000 description 1
- 206010028923 Neonatal asphyxia Diseases 0.000 description 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
- PICPVRGDLLNJAZ-SAABIXHNSA-N Oc1ccc(cc1)[C@H]1CC[C@@H](CC1)NCCOc1ccccc1 Chemical compound Oc1ccc(cc1)[C@H]1CC[C@@H](CC1)NCCOc1ccccc1 PICPVRGDLLNJAZ-SAABIXHNSA-N 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- YMDDQVXNITZOQA-UHFFFAOYSA-N methyl n-[4-(4-hydroxyphenyl)cyclohexyl]-n-(3-phenylpropyl)carbamate Chemical compound C1CC(C=2C=CC(O)=CC=2)CCC1N(C(=O)OC)CCCC1=CC=CC=C1 YMDDQVXNITZOQA-UHFFFAOYSA-N 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- KKFOSGQPKVPDTH-UHFFFAOYSA-N n-[4-(4-hydroxyphenyl)cyclohexyl]-2-methyl-2-phenoxypropanamide Chemical compound C1CC(C=2C=CC(O)=CC=2)CCC1NC(=O)C(C)(C)OC1=CC=CC=C1 KKFOSGQPKVPDTH-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000005809 status epilepticus Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/16—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring not being further substituted
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/23—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19976200P | 2000-04-26 | 2000-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200208177B true ZA200208177B (en) | 2004-02-11 |
Family
ID=22738909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200208177A ZA200208177B (en) | 2000-04-26 | 2002-10-10 | Cyclohexylamine derivative as subtype selective NMDA receptor antagonists. |
Country Status (27)
Country | Link |
---|---|
US (1) | US6919377B2 (xx) |
EP (1) | EP1278716B1 (xx) |
JP (1) | JP2003531187A (xx) |
KR (1) | KR20020093950A (xx) |
CN (1) | CN1441773A (xx) |
AP (1) | AP2002002664A0 (xx) |
AT (1) | ATE337292T1 (xx) |
AU (1) | AU2001255620A1 (xx) |
BG (1) | BG107258A (xx) |
BR (1) | BR0110247A (xx) |
CA (1) | CA2406272A1 (xx) |
CZ (1) | CZ20023479A3 (xx) |
DE (1) | DE60122495T2 (xx) |
EA (1) | EA200200952A1 (xx) |
EE (1) | EE200200612A (xx) |
ES (1) | ES2267759T3 (xx) |
HU (1) | HUP0300600A2 (xx) |
IL (1) | IL152424A0 (xx) |
IS (1) | IS6569A (xx) |
MA (1) | MA26895A1 (xx) |
MX (1) | MXPA02009659A (xx) |
NO (1) | NO20025136L (xx) |
OA (1) | OA12253A (xx) |
PL (1) | PL358584A1 (xx) |
SK (1) | SK15152002A3 (xx) |
WO (1) | WO2001081295A1 (xx) |
ZA (1) | ZA200208177B (xx) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0100623D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds IV |
US7064211B2 (en) * | 2002-03-22 | 2006-06-20 | Eisai Co., Ltd. | Hemiasterlin derivatives and uses thereof |
EP1575586A1 (en) * | 2002-12-17 | 2005-09-21 | Pfizer Japan Inc. | 2-pyridyl and 2-pyrimidyl cycloalkylene amide compounds as nr2b receptor antagonists |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
EP1758580A4 (en) * | 2004-06-24 | 2008-01-16 | Incyte Corp | N-SUBSTITUTED PIPERIDINE AND ITS USE AS A MEDICAMENT |
US7687665B2 (en) | 2004-06-24 | 2010-03-30 | Incyte Corporation | 2-methylprop anamides and their use as pharmaceuticals |
BRPI0514230A (pt) * | 2004-08-10 | 2008-06-03 | Incyte Corp | compostos de amido e seu uso como produtos farmacêuticos |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
EP2481408A3 (en) | 2007-03-01 | 2013-01-09 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
ES2377253T3 (es) * | 2007-09-12 | 2012-03-23 | Merz Pharma Gmbh & Co. Kgaa | Neramexano para uso en el tratamiento de tinitus subagudo |
WO2010021351A1 (ja) * | 2008-08-22 | 2010-02-25 | 第一三共株式会社 | シクロアルキルアミン誘導体 |
US8486940B2 (en) | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
EP2545047B9 (en) | 2010-03-10 | 2015-06-10 | Probiodrug AG | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
EP3071541B1 (en) | 2013-11-21 | 2023-06-07 | Marquette University | Substituted (4'-hydroxyphenyl)cycloalkane compounds and uses thereof as selective agonists of the estrogen receptor beta isoform |
US9187506B2 (en) | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
US9221796B2 (en) * | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
KR20190004743A (ko) * | 2016-05-04 | 2019-01-14 | 브리스톨-마이어스 스큅 컴퍼니 | 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법 |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW209868B (xx) * | 1991-04-04 | 1993-07-21 | Yoshitomi Pharmaceutical | |
CA2091204C (en) * | 1992-03-11 | 1997-04-08 | Ronald J. Mattson | Antiischemic-piperazinyl and piperidinyl-cyclohexanes |
DE4438020A1 (de) * | 1994-10-25 | 1996-05-02 | Thomae Gmbh Dr K | N-substituierte Arylcyclohexylacylamine, ihre Salze mit physiologisch verträglichen organischen oder anorganischen Säuren, Verfahren zur Herstellung dieser Verbindungen und diese enthaltende Arzneimittel |
JP3926390B2 (ja) * | 1995-10-26 | 2007-06-06 | 三菱ウェルファーマ株式会社 | β3作業薬として有用なフェニルエタノールアミン化合物、その製法およびその製造における中間体 |
PE20000728A1 (es) | 1998-06-26 | 2000-08-21 | Cocensys Inc | Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda |
EP0982026B1 (en) * | 1998-08-18 | 2006-05-17 | F. Hoffmann-La Roche Ag | Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers |
-
2001
- 2001-04-24 KR KR1020027014329A patent/KR20020093950A/ko not_active Application Discontinuation
- 2001-04-24 PL PL01358584A patent/PL358584A1/xx not_active Application Discontinuation
- 2001-04-24 AU AU2001255620A patent/AU2001255620A1/en not_active Abandoned
- 2001-04-24 JP JP2001578392A patent/JP2003531187A/ja active Pending
- 2001-04-24 AP APAP/P/2002/002664A patent/AP2002002664A0/en unknown
- 2001-04-24 EP EP01928803A patent/EP1278716B1/en not_active Expired - Lifetime
- 2001-04-24 US US10/258,721 patent/US6919377B2/en not_active Expired - Fee Related
- 2001-04-24 EE EEP200200612A patent/EE200200612A/xx unknown
- 2001-04-24 EA EA200200952A patent/EA200200952A1/ru unknown
- 2001-04-24 WO PCT/US2001/013176 patent/WO2001081295A1/en active IP Right Grant
- 2001-04-24 OA OA1200200326A patent/OA12253A/en unknown
- 2001-04-24 DE DE60122495T patent/DE60122495T2/de not_active Expired - Fee Related
- 2001-04-24 SK SK1515-2002A patent/SK15152002A3/sk unknown
- 2001-04-24 CZ CZ20023479A patent/CZ20023479A3/cs unknown
- 2001-04-24 AT AT01928803T patent/ATE337292T1/de not_active IP Right Cessation
- 2001-04-24 ES ES01928803T patent/ES2267759T3/es not_active Expired - Lifetime
- 2001-04-24 HU HU0300600A patent/HUP0300600A2/hu unknown
- 2001-04-24 CA CA002406272A patent/CA2406272A1/en not_active Abandoned
- 2001-04-24 MX MXPA02009659A patent/MXPA02009659A/es active IP Right Grant
- 2001-04-24 CN CN01808644A patent/CN1441773A/zh active Pending
- 2001-04-24 IL IL15242401A patent/IL152424A0/xx unknown
- 2001-04-24 BR BR0110247-8A patent/BR0110247A/pt not_active IP Right Cessation
-
2002
- 2002-09-27 IS IS6569A patent/IS6569A/is unknown
- 2002-10-10 ZA ZA200208177A patent/ZA200208177B/en unknown
- 2002-10-17 MA MA26873A patent/MA26895A1/fr unknown
- 2002-10-25 NO NO20025136A patent/NO20025136L/no not_active Application Discontinuation
- 2002-11-08 BG BG107258A patent/BG107258A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
KR20020093950A (ko) | 2002-12-16 |
AU2001255620A1 (en) | 2001-11-07 |
WO2001081295A1 (en) | 2001-11-01 |
DE60122495T2 (de) | 2007-03-29 |
EP1278716B1 (en) | 2006-08-23 |
CN1441773A (zh) | 2003-09-10 |
SK15152002A3 (sk) | 2003-05-02 |
BR0110247A (pt) | 2003-03-05 |
EE200200612A (et) | 2004-06-15 |
HUP0300600A2 (hu) | 2003-08-28 |
EA200200952A1 (ru) | 2003-02-27 |
MXPA02009659A (es) | 2003-03-10 |
NO20025136D0 (no) | 2002-10-25 |
CA2406272A1 (en) | 2001-11-01 |
BG107258A (bg) | 2003-07-31 |
DE60122495D1 (de) | 2006-10-05 |
IL152424A0 (en) | 2003-05-29 |
EP1278716A1 (en) | 2003-01-29 |
AP2002002664A0 (en) | 2002-12-31 |
NO20025136L (no) | 2002-12-20 |
CZ20023479A3 (cs) | 2003-04-16 |
JP2003531187A (ja) | 2003-10-21 |
IS6569A (is) | 2002-09-27 |
US6919377B2 (en) | 2005-07-19 |
MA26895A1 (fr) | 2004-12-20 |
ES2267759T3 (es) | 2007-03-16 |
OA12253A (en) | 2006-05-11 |
US20030236286A1 (en) | 2003-12-25 |
PL358584A1 (en) | 2004-08-09 |
ATE337292T1 (de) | 2006-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200208177B (en) | Cyclohexylamine derivative as subtype selective NMDA receptor antagonists. | |
EP2170334B1 (en) | Nmda receptor antagonists for neuroprotection | |
SK19512000A3 (sk) | 4-benzylpiperidínové alkylsulfoxidové heterocykly a ich použitie ako subtypovo selektívnych antagonistov nmda receptorov | |
EP1292581B1 (en) | Bicyclic cyclohexylamines and their use as nmda receptor antagonists | |
US6794402B2 (en) | Bicyclic cyclohexylamines and their use as NMDA receptor antagonists | |
MXPA02010863A (es) | Derivados de ciclohexilamina como subtipo de antagonistas del receptor nmda selectivo. | |
TWI625329B (zh) | 雜環乙醯胺化合物 |